Table 2.

Summary of serum TxB₂ concentration (ng/mL) at each time point—PD TxB₂ population (N = 21)

Time point median (min, max)	PL-ASA (N = 20)	EC-ASA (N = 18)	p-value
Baseline	96.53 (73.4, 117.3)	100.5 (71.2, 117.2)	0.2357
0.5 h post	96.10 (46.0, 117.4)	101.8 (75.6, 117.3)	0.0287
1 h post	87.84 (26.5, 114.5)	98.27 (68.2, 119.4)	0.0005
2 h post	77.62 (17.8, 97.6)	98.89 (61.8, 114.3)	< 0.0001
3 h post	72.06 (0.8, 93.1)	96.55 (56.7, 116.3)	0.0004
4 h post	66.16 (11.5, 98.6)	95.17 (40.9, 112.9)	0.0001
6 h post	72.92 (17.7, 94.8)	85.25 (11.8, 108.5)	0.0039
8 h post	72.80 (17.8, 99.3)	85.17 (6.3, 110.3)	0.0412
10 h post	65.59 (14.1, 99.7)	89.40 (54.2, 111.0)	0.0007
24 h post	73.66 (37.9, 97.3)	81.49 (39.3, 109.0)	0.0203

p-values were calculated based on a linear nixed-effects ANOVA model with sequence, period and treatment as fixed effects and subject as random effect

EC enteric-coated, PD pharmacodynamic, SD standard deviation, TxB₂ thromboxane B₂